Literature DB >> 19221502

DNA damage-dependent cyclin D1 proteolysis: GSK3beta holds the smoking gun.

Laura L Pontano1, J Alan Diehl.   

Abstract

Ubiquitin mediated degradation of cyclin D1 following the G(1)/S transition counters its mitogen-dependent accumulation during G(1) phase of the cell cycle. Although the cellular machinery responsible for this process has been identified, how this regulatory pathway interfaces with cellular stress responses, often referred to as checkpoints, remains to be established. One intensely investigated checkpoint is the cellular response to DNA damage. When DNA damage is sensed, the corresponding DNA damage checkpoint triggers the inhibition of CDK-dependent cell cycle progression, with arrest coordinated by induction of CDK inhibitors and rapid degradation of specific cyclins, such as cyclin D1. In recent work, we identified a phosphorylation- and Fbx4-dependent cyclin D1 degradation mechanism in response to genotoxic stress.(18) This work revealed that loss of cyclin D1 regulation compromises the intra-S-phase response to DNA damage, promoting genomic instability and sensitization of cells to S-phase chemotherapy, highlighting a potential therapeutic strategy for cancers exhibiting cyclin D1 accumulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221502      PMCID: PMC3703625          DOI: 10.4161/cc.8.6.7889

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  26 in total

1.  Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.

Authors:  J W Harbour; R X Luo; A Dei Santi; A A Postigo; D C Dean
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

2.  Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage.

Authors:  R Agami; R Bernards
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

Review 3.  Phosphoinositide 3-kinases: a conserved family of signal transducers.

Authors:  B Vanhaesebroeck; S J Leevers; G Panayotou; M D Waterfield
Journal:  Trends Biochem Sci       Date:  1997-07       Impact factor: 13.807

4.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

Authors:  J A Diehl; F Zindy; C J Sherr
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

Review 5.  Mammalian G1 cyclins.

Authors:  C J Sherr
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

6.  Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).

Authors:  M Cheng; V Sexl; C J Sherr; M F Roussel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 7.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

8.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

Authors:  J A Diehl; M Cheng; M F Roussel; C J Sherr
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

9.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

10.  Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein.

Authors:  M Hatakeyama; J A Brill; G R Fink; R A Weinberg
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

View more
  8 in total

1.  Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells.

Authors:  Katja Ester; Fran Supek; Kristina Majsec; Marko Marjanović; David Lembo; Manuela Donalisio; Tomislav Šmuc; Ivana Jarak; Grace Karminski-Zamola; Marijeta Kralj
Journal:  Invest New Drugs       Date:  2010-11-03       Impact factor: 3.850

Review 2.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

3.  S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons.

Authors:  Weizhen Ye; Stacy W Blain
Journal:  Brain       Date:  2010-07-17       Impact factor: 13.501

Review 4.  Proteomic identification of a direct role for cyclin d1 in DNA damage repair.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; David M Livingston; Piotr Sicinski
Journal:  Cancer Res       Date:  2012-08-22       Impact factor: 12.701

5.  P27(Kip1), regulated by glycogen synthase kinase-3β, results in HMBA-induced differentiation of human gastric cancer cells.

Authors:  Min Wei; Zhiwei Wang; Hongliang Yao; Zhongyin Yang; Qing Zhang; Bingya Liu; Yingyan Yu; Liping Su; Zhenggang Zhu; Qinlong Gu
Journal:  BMC Cancer       Date:  2011-03-27       Impact factor: 4.430

Review 6.  Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.

Authors:  Gabriele Di Sante; Jessica Pagé; Xuanmao Jiao; Omar Nawab; Massimo Cristofanilli; Emmanuel Skordalakes; Richard G Pestell
Journal:  Expert Rev Anticancer Ther       Date:  2019-06-20       Impact factor: 4.512

7.  Activation of G protein coupled estrogen receptor prevents chemotherapy-induced intestinal mucositis by inhibiting the DNA damage in crypt cell in an extracellular signal-regulated kinase 1- and 2- dependent manner.

Authors:  Guanyu Chen; Honghui Zeng; Xinyun Li; Jianbo Liu; Zhao Li; Runze Xu; Yuntao Ma; Chuanyong Liu; Bing Xue
Journal:  Cell Death Dis       Date:  2021-10-30       Impact factor: 8.469

8.  Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.

Authors:  Vishnu Kumarasamy; Amanda Ruiz; Ram Nambiar; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Oncogene       Date:  2019-11-19       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.